Place · Level 3 · Supplement
Coenzyme Q10 (Ubiquinone / Ubiquinol)
线粒体 ETC 辅基 · Q-SYMBIO 心衰 A 级 · 他汀肌痛 B 级 · 偏头痛 B 级 · 形态 + 剂量真相
Last updated
Story path
Chapter 1
Q10 · mitochondrial cofactor
Q10 · mitochondrial cofactor
Coenzyme Q10 (CoQ10, ubiquinone) is the cell's key electron shuttle between Complex I → II → III in the mitochondrial electron-transport chain (ETC) + one of the strongest intracellular lipid-soluble antioxidants.
Chemistry:
Benzoquinone ring + 10 isoprenoid side chains (the human form; mice have 9 → hence Q10)Oxidised (ubiquinone) ↔ reduced (ubiquinol) interconversion — the core of its electron-shuttle function
Body sources:
Endogenous synthesis (main): liver + heart + kidney + pancreas → shares the mevalonate pathway with cholesterol synthesisFood: organs (heart / liver / kidney) / sardines / beef / chicken — but < 5 mg/day, far less than endogenous
Why the atlas must cover Q10:
1. Effective for heart failure: Q-SYMBIO 2014 RCT (Mortensen, JACC HF) Level A evidence
2. Statin-induced muscle pain: partial Level B evidence, frequently used clinically
3. Migraine prevention: Level B (Sándor 2005, covered in atlas migraine story)
4. Mitochondrial disease: rare but Q10 is a core treatment
5. Massive anti-ageing marketing: real signal + lots of hype; the atlas debunks
The truth about "statin → ↓ Q10":
Statins inhibit HMG-CoA reductase → block cholesterol synthesisThe upstream of that pathway is also Q10 synthesis → blood Q10 ↓ 16-40% (Päivä 2005)But: the hypothesis "statin lowers Q10 → worsens heart failure" has no RCT evidence"Statin myalgia" may be partly Q10-related — Level B evidence that Q10 reduces myalgia (Banach 2015 meta)
Blood Q10 ≠ tissue Q10:
90% of plasma Q10 is bound to lipoproteins (LDL / HDL)"High blood Q10" often only reflects high blood lipid (lots of LDL)Actual cellular / cardiac / muscle Q10 correlates weakly with plasmaThis is one reason Q10 RCT interpretation is complicated
Chemistry:
Benzoquinone ring + 10 isoprenoid side chains (the human form; mice have 9 → hence Q10)Oxidised (ubiquinone) ↔ reduced (ubiquinol) interconversion — the core of its electron-shuttle function
Body sources:
Endogenous synthesis (main): liver + heart + kidney + pancreas → shares the mevalonate pathway with cholesterol synthesisFood: organs (heart / liver / kidney) / sardines / beef / chicken — but < 5 mg/day, far less than endogenous
Why the atlas must cover Q10:
1. Effective for heart failure: Q-SYMBIO 2014 RCT (Mortensen, JACC HF) Level A evidence
2. Statin-induced muscle pain: partial Level B evidence, frequently used clinically
3. Migraine prevention: Level B (Sándor 2005, covered in atlas migraine story)
4. Mitochondrial disease: rare but Q10 is a core treatment
5. Massive anti-ageing marketing: real signal + lots of hype; the atlas debunks
The truth about "statin → ↓ Q10":
Statins inhibit HMG-CoA reductase → block cholesterol synthesisThe upstream of that pathway is also Q10 synthesis → blood Q10 ↓ 16-40% (Päivä 2005)But: the hypothesis "statin lowers Q10 → worsens heart failure" has no RCT evidence"Statin myalgia" may be partly Q10-related — Level B evidence that Q10 reduces myalgia (Banach 2015 meta)
Blood Q10 ≠ tissue Q10:
90% of plasma Q10 is bound to lipoproteins (LDL / HDL)"High blood Q10" often only reflects high blood lipid (lots of LDL)Actual cellular / cardiac / muscle Q10 correlates weakly with plasmaThis is one reason Q10 RCT interpretation is complicated
机制 · 电子在膜里怎么被接住又递出去
把上一屏那句大白话展开到分子层面。辅酶 Q10 (CoQ10, ubiquinone) 是细胞线粒体电子传递链 (ETC) 中 Complex I → II → III 之间的关键电子穿梭体, 也是细胞内最强的脂溶抗氧化剂之一。
化学:
苯醌环 + 10 个异戊二烯侧链 (人类版本; 老鼠 9 个 → 故名 Q10)氧化态 (ubiquinone) ↔ 还原态 (ubiquinol) 互转, 这是它电子穿梭功能的核心
这两条不是化学冷知识, 它们就是这个分子的工作本身。
那条长尾巴决定了它待在哪里。 异戊二烯侧链是一串油性碳链, 又长又不亲水, 所以这个分子只能待在线粒体内膜的油层里, 像浮标一样卡在两层脂质中间横向滑动。它不进水相、不被血流冲走; 也正因为如此, 它是少数能在膜内部干活的抗氧化剂。
头上那个环决定了它做什么。 苯醌环一次接一个电子: 接一个变成半还原的中间态, 再接一个就成了完全还原的 ubiquinol; 把两个电子卸给下游, 又变回 ubiquinone。所谓氧化态与还原态互转, 直白说就是装货和卸货这两个动作在膜里来回重复。每一次装卸都伴随着质子被推到膜外, 而膜外积起来的质子压差, 就是后面拧出 adenosine triphosphate: The cell's universal energy currency — almost everything that costs energy spends it. 的那股劲。
为什么它在流水线上不可替代。 传递链前段有两个进料口: 一个收糖和脂肪拆解出来的还原当量, 另一个从三羧酸循环里直接接一手。这两条线不并成一条, 而是都把电子交给同一个搬运工。所以它是整条链的汇合口——它不够, 两条进料线一起堵在前面。
为什么心脏最先出问题。 心肌不是偶尔用力, 而是一刻不停: 收缩要花 ATP, 收缩完把钙搬回仓库、让肌肉重新松开, 同样要花 ATP。心肌细胞里塞满线粒体正是为此。一个把产能压到极限的组织, 对流水线上任何一环的效率下降都最敏感——同样幅度的下滑, 在皮肤上可能什么都感觉不到, 在心脏上就是收缩弱一点、松开慢一点。
它顺带干的另一件事。 膜里的脂肪酸一旦被自由基抢走一个电子, 就会连锁氧化下去, 一个拉一个。还原态的 ubiquinol 能抢先把电子递出去, 把这条连锁掐断; 递完它自己变回氧化态, 再被流水线重新装满。这就是它被叫作膜内脂溶抗氧化剂的原因——重点不是它的抗氧化能力有多强, 而是它人就在现场, 而且现场有一条把它重新充满的流水线。
来源 · 他汀为什么会把它一起拽低
身体来源:内源合成 (主要): 肝 + 心 + 肾 + 胰, 与胆固醇合成共享甲羟戊酸通路 (mevalonate pathway)食物: 内脏 (心、肝 / 肾) / 沙丁鱼、牛肉、鸡, 但每日 < 5 mg, 远小于内源
先看清一件事: 靠吃是补不上来的。日常饮食一天提供的量和身体自己造出来的量不在一个量级, 所以关于它的争论从来不是吃什么, 而是要不要额外补。
Statin → Q10 ↓ 的真相:
他汀抑制 HMG-CoA reductase → 阻断胆固醇合成同一通路上游也是 Q10 合成, 血 Q10 水平 ↓ 16-40% (Päivä 2005)但他汀降 Q10 → 心衰恶化的假说没有 RCT 证据他汀肌痛可能与 Q10 部分相关, B 级证据显示补 Q10 可减肌痛 (Banach 2015 meta)
共享通路具体共享在哪一步?
身体造胆固醇, 和造这个分子那条油性尾巴, 用的是同一批积木。甲羟戊酸通路先把小分子拼成一种通用的异戊二烯砖块, 再由不同车间领走: 一条线把砖块继续拼成胆固醇, 另一条线把砖块接成长长的尾巴, 装到苯醌环上。他汀掐的是这条通路最上游那道闸 (HMG-CoA reductase), 也就是砖块厂的总开关。总开关拧小, 下游两个车间一起少料——这不是副作用意义上的意外, 而是这条通路的结构决定的。
但这只解释了血里的水平为什么会跟着降, 没有解释降了会怎样。后面这一步才是关键, 而它其实是三段独立的链条:
血里降了 → 已被反复测到, 是事实组织里降了多少 → 没有可靠答案, 因为血和组织的相关性本来就弱, 下一页展开组织降了会不会引起症状 → 这才是他汀肌痛假说要回答的, 目前只有 B 级证据
把这三段并成一句他汀伤心脏, 所以要补, 中间跳过了两次没有被证据填上的空白。这也是为什么站里对心衰恶化那个假说的措辞是没有 RCT 证据, 而不是已被否定——前者说的是没人验过, 后者说的是验过且不成立, 两句话差得很远。
血里的数字 ≠ 组织里的量
血 Q10 水平 ≠ 组织 Q10:血浆 90% Q10 与脂蛋白 (LDL / HDL) 结合血 Q10 高经常只反映血脂高 (LDL 多)实际细胞、心肌、肌肉 Q10 与血浆相关性弱这是 Q10 RCT 解读复杂的原因之一
为什么会这样? 上一页那条油性尾巴又是答案。
这个分子不溶于水, 而血浆基本上就是水。它没法自己漂着走, 只能钻进脂蛋白这些运油的小船里搭便车。于是抽血量到的其实是船上装了多少, 而不是工厂里存了多少。一个血脂偏高的人船多, 数就高; 这并不等于他的心肌里更充裕。
反过来同样成立: 一个人把血脂降下来, 血里这个数也会跟着掉, 但那未必意味着组织里少了什么。看着化验数字调补剂在这里站不住脚——数字反映的是运输系统的状态, 不是使用现场的库存。
这一点会一路影响后面每一段的解读:
他汀让血里的水平掉了 → 不能直接推出肌肉里掉了同样多补进去让血里的水平升上来 → 也不能直接推出心肌里升上来所以试验必须看硬终点: 有没有少住院、少死人, 而不是血里的数字好不好看
心衰那项试验之所以分量重, 正是因为它绕开了这个坑: 它没有拿血里的浓度当成绩单, 而是直接数了人。
Q10 deficiency populations + testing limits
"Measure blood Q10 → decide whether to supplement" is not as simple as it looks. This page unpacks it.Populations genuinely at risk of Q10 deficiency:
1. Older adults (60+)
Endogenous Q10 synthesis falls 10-15% every decadeAt 80, cardiac / liver / kidney Q10 concentrations ≈ 50-60% of values at 20But "do I need to supplement" depends on symptoms, not numbers
2. Long-term statin use (atlas cardiovascular)
Shared mevalonate pathway with cholesterol synthesis → Q10 ↓ 16-40%Not every statin user has muscle pain — most do notSAMS (Statin-Associated Muscle Symptoms) rate: ~ 7-29% (highly variable; placebo-controlled true rate only 1-2%)Q10 supplementation for SAMS has Level B evidence — worth a trial, not mandatory
3. Heart failure (NYHA III-IV)
Myocardial Q10 correlates inversely with HF severityQ-SYMBIO RCT confirmed Q10 supplementation improves hard endpointsThe patients meeting trial-entry criteria gain the most
4. Migraine
Sándor 2005 Neurology RCT: 100-300 mg/day × 3 months → migraine frequency ↓ 50%Atlas migraine trio (Mg + B2 + Q10)
5. Mitochondrial diseases (rare)
MELAS / Leber optic neuropathy / Friedreich ataxia, etc.Neurology / metabolic specialist guidance; Q10 is usually a main treatment (rather than adjunct)
6. Infertility / IVF + advanced age (women 35+)
The only human RCT is Bentov 2014 (600 mg/day, women 35-43 in IVF-ICSI). It was stopped early over polar-body-biopsy safety concerns with just 24 completers; aneuploidy 46.5% vs 62.8% and clinical pregnancy 33% vs 26.7% — no significant difference, and the authors call it underpoweredSo the enthusiasm here rests on animal and mechanistic work, not on a positive human trialSome fertility centers use it empirically; not standard IVF protocol, but can be discussed with reproductive specialists
Blood Q10 testing limitations:
Normal range: 0.4-1.5 µg/mL (most labs)Deficiency definition: < 0.5 µg/mLBut:90% of plasma Q10 is bound to LDL/HDL → high LDL → high blood Q10 but not necessarily more tissue Q10Tissue / myocardial Q10 is what mattersPlasma-to-myocardial correlation r ~ 0.3-0.5 (weak-to-moderate)Clinical reality: most clinicians do not measure Q10 levels — empirical supplementation + watch symptom improvementRare mitochondrial disease / deficiency syndromes (severe Q10 deficiency): muscle biopsy → measure muscle Q10
False positives / marketing traps:
"Q10 testing packages" (for healthy people): no indication, numbers have no clinical meaning"All older adults should take Q10": no hard evidence, look at symptoms"Q10 anti-ageing reduces wrinkles": clinical evidence weakReal signals: heart failure + SAMS + migraine prevention + mitochondrial disease
Chapter 2
Q-SYMBIO · HF A-tier
Q-SYMBIO · HF A-tier
The Q-SYMBIO Trial (Mortensen 2014 JACC Heart Failure) — the most important Q10 RCT on the atlas:
Design:
N = 420 moderate-to-severe HF patients (NYHA III-IV) on standard HF therapy100 mg × 3 times/day = 300 mg/day ubiquinone × 2 yearsPrimary endpoint: MACE (CV events + HF worsening + death)
Results:
MACE ↓ 43% (29% vs 15%, p = 0.003)All-cause death ↓ 42% (18% vs 10%, p = 0.018)CV death ↓ 43%Improved NYHA functional classSide effects equivalent to placebo
Why this matters:
Level A (one large RCT + positive hard endpoints) is extremely rare for supplements in cardiology2017 ESC HF guidelines + some US CV societies recommend Q10 as an adjunct for HFDoes not replace first-line ACEi/ARB/β-blocker/SGLT2
Mechanism (proposed):
The myocardium consumes large amounts of adenosine triphosphate: The cell's universal energy currency — almost everything that costs energy spends it. per second — mitochondrial ETC is centralIn HF, myocardial Q10 ↓ + impaired mitochondrial functionSupplemental Q10 → improved cardiac ATP production + antioxidant effect
Follow-up / replication:
Mortensen 2019: a European sub-group analysis of the same trial, pointing the same way — a sub-group, not a longer follow-upCochrane: the 2014 version concluded flatly that no conclusions could be drawn — it had no clinical-event data at all, and its search closed before Q-SYMBIO was even published. The 2021 update (Al Saadi) does report lower all-cause mortality (RR 0.58, 0.35-0.95), but that estimate comes from one 420-patient study — Q-SYMBIO itself. So it is still not an independent replicationControversy: Q-SYMBIO was single-center + industry-funded (Pharma Nord), raising bias concerns; awaiting larger independent replication
Statin-associated muscle symptoms (SAMS):
Banach 2015 meta-analysis (12 RCTs): Q10 ~ 100-300 mg/day → significant SAMS improvementTaylor 2015 *Atherosclerosis* RCT: negative — Q10 did not reduce muscle pain in confirmed statin myalgia (double-blind crossover)Consensus: Level B evidence, some patients benefit; not all SAMS reflects Q10 deficiencyClinical practice: SAMS patients may try Q10 100-200 mg/day × 2-3 months and gauge symptom improvement
Dosing:
HF: 300 mg/day in 3 divided doses (Q-SYMBIO dose)Statin myalgia: 100-200 mg/dayMigraine prevention: 100-300 mg/day (Sándor 2005)General wellness: 100 mg/day (weak evidence, mostly marketing-driven)
Design:
N = 420 moderate-to-severe HF patients (NYHA III-IV) on standard HF therapy100 mg × 3 times/day = 300 mg/day ubiquinone × 2 yearsPrimary endpoint: MACE (CV events + HF worsening + death)
Results:
MACE ↓ 43% (29% vs 15%, p = 0.003)All-cause death ↓ 42% (18% vs 10%, p = 0.018)CV death ↓ 43%Improved NYHA functional classSide effects equivalent to placebo
Why this matters:
Level A (one large RCT + positive hard endpoints) is extremely rare for supplements in cardiology2017 ESC HF guidelines + some US CV societies recommend Q10 as an adjunct for HFDoes not replace first-line ACEi/ARB/β-blocker/SGLT2
Mechanism (proposed):
The myocardium consumes large amounts of adenosine triphosphate: The cell's universal energy currency — almost everything that costs energy spends it. per second — mitochondrial ETC is centralIn HF, myocardial Q10 ↓ + impaired mitochondrial functionSupplemental Q10 → improved cardiac ATP production + antioxidant effect
Follow-up / replication:
Mortensen 2019: a European sub-group analysis of the same trial, pointing the same way — a sub-group, not a longer follow-upCochrane: the 2014 version concluded flatly that no conclusions could be drawn — it had no clinical-event data at all, and its search closed before Q-SYMBIO was even published. The 2021 update (Al Saadi) does report lower all-cause mortality (RR 0.58, 0.35-0.95), but that estimate comes from one 420-patient study — Q-SYMBIO itself. So it is still not an independent replicationControversy: Q-SYMBIO was single-center + industry-funded (Pharma Nord), raising bias concerns; awaiting larger independent replication
Statin-associated muscle symptoms (SAMS):
Banach 2015 meta-analysis (12 RCTs): Q10 ~ 100-300 mg/day → significant SAMS improvementTaylor 2015 *Atherosclerosis* RCT: negative — Q10 did not reduce muscle pain in confirmed statin myalgia (double-blind crossover)Consensus: Level B evidence, some patients benefit; not all SAMS reflects Q10 deficiencyClinical practice: SAMS patients may try Q10 100-200 mg/day × 2-3 months and gauge symptom improvement
Dosing:
HF: 300 mg/day in 3 divided doses (Q-SYMBIO dose)Statin myalgia: 100-200 mg/dayMigraine prevention: 100-300 mg/day (Sándor 2005)General wellness: 100 mg/day (weak evidence, mostly marketing-driven)
试验本身 · 机制推测到哪一步为止
机制 (推测):心肌每秒消耗大量 ATP, 线粒体 ETC 是核心心衰时心肌 Q10 ↓ + 线粒体功能差补 Q10 改善心肌 ATP 产生 + 抗氧化
推测这两个字要认真对待。上面三条里, 第一条是生理常识, 第二条是测出来的相关, 只有第三条是从试验结果反推出来的——研究者看到人活得更久, 于是回头假设走的是能量供应这条路; 没有人打开活人的心脏去量那里的能量周转有没有变。所以准确的说法是结果确凿、路径待证, 而不是已经证明它修好了线粒体。
为什么衰竭的心脏对能量特别敏感, 值得再往下说一层。
健康的心脏泵血有余量: 效率掉一点, 靠储备顶回来, 你什么都感觉不到。衰竭的心脏已经在用最大力气维持最低产出, 余量没了。这时候流水线上任何一环慢下来, 都会直接变成两件事——射出去的血更少, 以及下一次松开得更慢。
松开慢这件事常被忽略, 但它同样致命: 心脏要先充分松开, 血才灌得进来, 下一次才有东西可泵。而松开不是被动的, 它靠一台泵把收缩时放出来的钙重新搬回仓库, 那台泵烧的也是 adenosine triphosphate: The cell's universal energy currency — almost everything that costs energy spends it.。所以能量不足在衰竭的心脏上是双向扣分: 泵出去这一边弱, 灌进来这一边也慢。这就是为什么同样一点效率下滑, 在健康人身上无声无息, 在心衰病人身上却能变成能不能爬完一层楼的差别。
后续、复制:
Mortensen 2019: 同一试验的欧洲亚组分析, 方向一致 —— 是亚组, 不是更长的随访Cochrane: 2014 那一版的结论是得不出结论 —— 它手上一条临床事件数据都没有, 而且检索截止时间早于 Q-SYMBIO 发表。2021 更新版 (Al Saadi) 确实报了全因死亡率下降 (RR 0.58, 0.35-0.95), 但那个估计来自唯一一项 420 人的研究, 就是 Q-SYMBIO 本身 —— 所以它仍然不是独立复制争议: Q-SYMBIO 单中心 + 资金来源 (Pharma Nord) 引发偏倚担心, 复制仍待大型独立 RCT
单中心 + 厂家出钱为什么要记一笔? 不是说结果是假的, 而是说满足这两个条件时效应量偏大的历史概率更高。单中心意味着病人筛选、给药方式、随访强度都由同一套人马控制, 换个地方不一定复现; 资金来源影响的则是哪些分析会被写出来。
所以读它的正确姿势是: 把它当成一个足够强、值得据此行动的信号, 同时承认它还没有被独立的第二家做出来。这跟因为有利益相关所以不信是两回事——后者是懒惰的怀疑, 前者才是把不确定性放在正确位置上。
他汀肌痛: 两项试验为什么打架
他汀诱发肌痛 (SAMS):Banach 2015 meta (12 RCT): Q10 100-300 mg/天, SAMS 症状显著改善Taylor 2015 *Atherosclerosis* RCT: 阴性 —— 在确诊的他汀肌痛患者里, Q10 与安慰剂没有差别 (双盲交叉)共识: B 级证据, 部分患者受益; 不是所有 SAMS 都 Q10 缺乏临床实操: SAMS 患者值得试 Q10 100-200 mg/天 × 2-3 月, 看症状改善
一项汇总分析说有效, 一项随机对照试验说无效。这通常不是谁做错了, 而是入组的人根本不是同一批。
他汀肌痛这个标签底下混着至少三种人:
真的因为这个药而痛的人本来就会腰酸背痛、恰好也在吃他汀的人知道自己在吃一种据说会让肌肉痛的药, 于是对身上的酸痛格外敏感的人
只有第一种人有机会从补充里获益。如果一项研究招进来的大多是后两种, 那么就算补充对第一种人真的管用, 平均下来也会被稀释成看不出差别。反过来, 一项事先筛掉了停药后症状消失、再吃又出现的人的研究, 阳性信号自然更明显。上面那两项研究的方向差异, 多半就落在这里。
还有一层前面已经埋好了: 他汀确凿降低的是血里的水平, 而肌肉里到底降了多少并没有可靠答案。所以补回来就不痛了这条链, 中间那一环从来没有被直接量过——这也是它停在 B 级而不是 A 级的原因。
于是共识落在值得一试, 不是必备这个位置: 它便宜、安全、试几个月就知道有没有用; 而备选方案 (换药、减量、隔日给药) 每一个都比它折腾, 也都要医生参与。先试成本最低的那个, 是这里唯一说得通的顺序。
剂量 · 为什么要分成几次吃
剂量:心衰: 300 mg/天分 3 次 (Q-SYMBIO 剂量)他汀肌痛: 100-200 mg/天偏头痛预防: 100-300 mg/天 (Sándor 2005)一般保健: 100 mg/天 (证据弱, 多营销驱动)
分次不是仪式感, 它跟吸收那一步的物理限制直接有关。
这个分子油溶、个头大, 进血的唯一通道是先在小肠里被胆汁和食物脂肪一起裹成微小的油滴, 再随着这些油滴被肠壁吸收、送进淋巴。这条通道有容量上限: 一次吞下的量越大, 能被裹进去的比例越低, 剩下的直接从肠道走掉。所以同样的总量拆成几次、每次都配一口油, 实际进到血里的会比一次吞完更多。
心衰那个用法之所以写成分次给, 而不是早上一把吞完, 原因就在这里。
对读者更实用的一条推论: 如果你把每天的量往上加却没感觉到差别, 先别急着继续加。更可能有效的动作是把同样的量拆开、并且确保每次都跟含油脂的食物一起吃。瓶子上的数字是你吞下去的量, 不是进到身体里的量, 这两个数在这个分子身上差得特别远。
Chapter 3
Form + bioavailability
Form + bioavailability
Ubiquinone vs Ubiquinol — which is better?
Ubiquinone (oxidised, traditional):
Cheap ($0.10-0.20 per 100 mg)Most long-term data (most RCTs use this form)Reduced to ubiquinol in the body before actingAbsorption strongly synergised by a fatty meal — < 25% fasting, > 70% with a fatty meal
Ubiquinol (reduced, "active"):
2-4× more expensive ($0.40-0.80 per 100 mg)Claimed bioavailability 3-4× ubiquinone (manufacturer)However: independent RCTs show similar total plasma Q10 rises (both ultimately appear as ubiquinol in blood)Possibly better suited to: older adults / HF / severe oxidative stress (impaired endogenous reduction)Clinical evidence far less than ubiquinone
Conclusion:
Most people: ubiquinone + with a fatty meal = best valueOlder (70+) / HF / high-dose needs: ubiquinol may offer slight advantage, but 1-3× the price is not necessarily worth itDo not pay a premium for "active" marketing — look at measured outcomes (heart rate / myalgia improvement / headache frequency)
Forms:
Softgels (oil-filled): recommended — built-in lipid vehicle, consistent absorptionTablets / powder: must be taken with a fatty meal, otherwise absorption is poor"Water-soluble nano / microcapsule": some high-bioavailability forms, but expensive + clinical difference not always significant
Nutrient / drug interactions:
Vitamin K: both fat-soluble, can be taken togetherWarfarin: Q10 structure resembles vitamin K — may antagonise warfarin, warfarin users must inform their physician + monitor INRAntihypertensives: Q10 may lower BP 5-10 mmHg, monitor if on BP drugsβ-blockers: Q10 may mildly counter their heart-rate-lowering effectChemotherapy: some Q10 + chemotherapy combination studies; discuss with oncology
Ubiquinone (oxidised, traditional):
Cheap ($0.10-0.20 per 100 mg)Most long-term data (most RCTs use this form)Reduced to ubiquinol in the body before actingAbsorption strongly synergised by a fatty meal — < 25% fasting, > 70% with a fatty meal
Ubiquinol (reduced, "active"):
2-4× more expensive ($0.40-0.80 per 100 mg)Claimed bioavailability 3-4× ubiquinone (manufacturer)However: independent RCTs show similar total plasma Q10 rises (both ultimately appear as ubiquinol in blood)Possibly better suited to: older adults / HF / severe oxidative stress (impaired endogenous reduction)Clinical evidence far less than ubiquinone
Conclusion:
Most people: ubiquinone + with a fatty meal = best valueOlder (70+) / HF / high-dose needs: ubiquinol may offer slight advantage, but 1-3× the price is not necessarily worth itDo not pay a premium for "active" marketing — look at measured outcomes (heart rate / myalgia improvement / headache frequency)
Forms:
Softgels (oil-filled): recommended — built-in lipid vehicle, consistent absorptionTablets / powder: must be taken with a fatty meal, otherwise absorption is poor"Water-soluble nano / microcapsule": some high-bioavailability forms, but expensive + clinical difference not always significant
Nutrient / drug interactions:
Vitamin K: both fat-soluble, can be taken togetherWarfarin: Q10 structure resembles vitamin K — may antagonise warfarin, warfarin users must inform their physician + monitor INRAntihypertensives: Q10 may lower BP 5-10 mmHg, monitor if on BP drugsβ-blockers: Q10 may mildly counter their heart-rate-lowering effectChemotherapy: some Q10 + chemotherapy combination studies; discuss with oncology
两种形态的完整账 · 价格 · 剂型
Ubiquinone vs Ubiquinol — 哪个更好?Ubiquinone (氧化型, 传统):
价格便宜 ($0.10-0.20/100mg)长期数据多 (大部分 RCT 用这个)体内被还原为 ubiquinol 后起作用吸收与脂餐显著协同, 上一屏那两个吸收率就是这么来的
Ubiquinol (还原型, 活性):
价格贵得多 ($0.40-0.80/100mg)生物利用度声称比 ubiquinone 高 3-4 倍 (厂家)但独立 RCT 显示血浆 Q10 总水平上升相似 (两者最终都是 ubiquinol 在血中)可能更适合老年人、心衰、严重氧化应激 (内源还原能力下降)临床证据远少于 ubiquinone
结论:
大多数人 ubiquinone + 与脂餐同服 = 性价比最优老年 (70+) / 心衰、大剂量需求: ubiquinol 可能略有优势, 但多 1-3 倍价格不一定值不要因为活性营销付溢价, 看实测效果 (心率、肌痛改善、头痛频率)
活性型这个卖点为什么会缩水? 因为氧化态和还原态之间的转换在身体里本来就是双向的、而且随时在发生——那正是这个分子的工作方式, 装货卸货来回切换。你吞下哪一种, 肠壁和血液都会把它调成当下需要的比例。所以买还原态就等于直接补到位这个说法, 把一个动态平衡当成了一次性状态。真正卡住吸收的不是它带不带电子, 而是它能不能被油滴裹住进肠壁——而那一步两种形态遇到的是同一个瓶颈。
剂型:
软胶囊 (含油): 推荐, 自带脂质载体, 吸收稳定片剂、粉: 必须与脂餐同服, 否则吸收差水溶纳米、微囊: 部分高生物利用度形态, 但贵且临床差异未必显著
把剂型这一栏和上面那个瓶颈对起来看, 逻辑就很清楚了: 软胶囊之所以稳, 是因为它把那口油预先装在了壳里, 于是你吃不吃脂餐都有一层保底; 片剂和粉没有这层保底, 完全指望你那一餐里有没有脂肪; 而各种纳米、微囊做的事情, 本质上也是替你完成把它裹成足够小的油滴这一步。所以它们不是三种不同的技术路线, 而是同一个物理问题的三种解法, 差别只在谁替你出这份力、以及你为此多付多少钱。
药物互作 · 吃华法林 / 降压药 / β 阻滞剂的人看这页
与营养素、药物互作:维生素 K: 同脂溶, 可同时补华法林 (Warfarin): Q10 结构与维 K 相似, 可能拮抗华法林作用, 服华法林者必须告知医生 + 监测 INR降压药: Q10 可能降血压 5-10 mmHg, 服降压药者监测β-blocker: Q10 可能轻度抵消其降心率作用化疗: 部分 Q10 + 化疗联用研究, 与肿瘤科医生讨论
为什么偏偏是华法林? 因为长得像在这里是有具体含义的。华法林起效靠的是拦住维生素 K 的回收再利用, 让身体没法把几个凝血因子加工成能干活的形态, 于是血凝得慢。而这个分子的结构和维生素 K 同属一类: 一个醌环, 加一条油性长尾。结构相近意味着它有机会挤进同一批酶的作用位置, 把华法林的效果往回拉一点点。
所以这里的风险不是中毒, 而是你的抗凝强度悄悄变了——而这件事只有验血才看得出来。剂量稳定、指标稳定的人, 是最容易忽略这条的: 你没有任何不舒服, 直到出问题那天。上面那句必须告知医生 + 监测 INR要照做, 不是客套。
降压和降心率那两条同理: 它们不是危险的相互作用, 而是同方向叠加。你原本靠药物把血压压到某个位置, 现在多了一份来自补剂的推力, 结果可能比目标更低。处理方式也很朴素——开始补的头一两个月自己多量几次血压和心率, 有明显下移就把数字带去给开药的医生看, 由他决定要不要调药。
还有一条容易被误读: 表里同脂溶, 可同时补说的是维生素 K 和它可以一起吃, 这跟华法林那条不矛盾。前者讲的是两种营养素在吸收上不打架, 后者讲的是补剂和抗凝药之间的药效关系。分清楚这两件事, 才不会得出吃华法林就不能碰维生素 K这种既错又危险的结论。
Chapter 4
Decision tree
Decision tree
Who is Q10 right for?
Level A indications (clear evidence):
Moderate-to-severe heart failure (NYHA II-IV): 300 mg/day (Q-SYMBIO), combined with first-line HF therapyStatin-induced myalgia (SAMS): 100-200 mg/day × 2-3 months trial
Level B indications:
Migraine prevention (one of the atlas migraine trio): 100-300 mg/dayMitochondrial diseases (rare, specialist-guided)Infertility / IVF: downgraded — the one human RCT (Bentov 2014) was terminated early and found no significant difference
Level C / marketing-driven (weak evidence):
"Anti-ageing / wrinkle reduction""Athletic performance""Fatigue" (except clear mitochondrial disease)"Periodontal disease"
Who should not supplement:
Pregnancy / breastfeeding: lacks dataWarfarin users: monitor INR, discuss with the physicianChildren: only with mitochondrial-disease indication
When to expect effect:
HF / myalgia / migraine: 8-12 weeks before judging; don't quit at 2 weeksPlasma Q10: steady state at 4-6 weeksTrack symptoms in parallel for an objective assessment
Cost-effectiveness:
Ubiquinone 100 mg × 3/day × 1 year ≈ ¥600-1200 (high-quality brand)vs Q-SYMBIO clinical benefit: extremely high ROI in HF patientsvs "wellness" use: not cost-effective
Connections to other atlas stories:
One of the atlas migraine trioalpha-lipoic-acid L4 five-cofactor set (B1/B2/B3/B5 + ALA + Q10 in the mitochondrial series)niacin-b3/nad + riboflavin-b2/flavins L4 (ETC partners)cardiovascular/atherosclerosis L4 (HF context)Statin / dyslipidemia patients: report-rule trigger
Atlas position: Q10 is one of the few supplements on this continent with real hard-endpoint RCT evidence — especially in heart failure. It is not an "anti-ageing miracle pill" but a worthwhile adjunctive therapy in specific indications.
Level A indications (clear evidence):
Moderate-to-severe heart failure (NYHA II-IV): 300 mg/day (Q-SYMBIO), combined with first-line HF therapyStatin-induced myalgia (SAMS): 100-200 mg/day × 2-3 months trial
Level B indications:
Migraine prevention (one of the atlas migraine trio): 100-300 mg/dayMitochondrial diseases (rare, specialist-guided)Infertility / IVF: downgraded — the one human RCT (Bentov 2014) was terminated early and found no significant difference
Level C / marketing-driven (weak evidence):
"Anti-ageing / wrinkle reduction""Athletic performance""Fatigue" (except clear mitochondrial disease)"Periodontal disease"
Who should not supplement:
Pregnancy / breastfeeding: lacks dataWarfarin users: monitor INR, discuss with the physicianChildren: only with mitochondrial-disease indication
When to expect effect:
HF / myalgia / migraine: 8-12 weeks before judging; don't quit at 2 weeksPlasma Q10: steady state at 4-6 weeksTrack symptoms in parallel for an objective assessment
Cost-effectiveness:
Ubiquinone 100 mg × 3/day × 1 year ≈ ¥600-1200 (high-quality brand)vs Q-SYMBIO clinical benefit: extremely high ROI in HF patientsvs "wellness" use: not cost-effective
Connections to other atlas stories:
One of the atlas migraine trioalpha-lipoic-acid L4 five-cofactor set (B1/B2/B3/B5 + ALA + Q10 in the mitochondrial series)niacin-b3/nad + riboflavin-b2/flavins L4 (ETC partners)cardiovascular/atherosclerosis L4 (HF context)Statin / dyslipidemia patients: report-rule trigger
Atlas position: Q10 is one of the few supplements on this continent with real hard-endpoint RCT evidence — especially in heart failure. It is not an "anti-ageing miracle pill" but a worthwhile adjunctive therapy in specific indications.
完整清单 · B 级 / C 级 / 谁不该补 / 什么时候评估
B 级适应症:偏头痛预防 (atlas migraine 三剑客之一): 100-300 mg/天线粒体疾病 (罕见, 专科指导)不孕、体外受精 —— 已从 B 级下调: 唯一的人体 RCT (Bentov 2014) 提前终止且无显著差异, 撑不起 B 级
C 级、营销驱动 (证据弱):
抗衰、减皱运动表现疲劳 (除明确线粒体病外)牙周病
C 级的意思要说清楚: 不是已经证明没用, 而是没被好好测过, 或者测了没测出来。这两者在决策上后果一样 (别为它付钱), 但在理解上完全不同——前者关上了门, 后者只是还没开灯。区分它的意义在于: 当某天真出现一项设计干净的试验时, 你知道该更新的是哪一档, 而不是整个推翻。
谁不该补:
怀孕、哺乳: 缺数据华法林服用者: 监测 INR, 与医生协商儿童: 仅线粒体疾病指征下
缺数据和已知有害是两件事, 但在孕期它们的处理方式一样: 不用。因为孕期任何一次暴露的下行风险由另一个人承担, 而收益只是可能。这不是对这个分子的特殊判决, 而是所有证据不足的补剂在孕期共用的默认规则。
何时见效:
心衰、肌痛、偏头痛: 上一屏那个时间窗才看得出效果, 不要试 2 周放弃血 Q10 水平: 4-6 周达稳态同时记录症状才能客观评估
这三行连起来读, 才知道为什么要等那么久。血里的浓度几周就到稳态了, 但那只是运输系统装满; 组织里真正积起来更慢, 而症状是组织层面的事, 还要再往后排。所以吃了几周没感觉在这里几乎没有信息量——你观察的时点根本没到该有变化的地方。反过来这也解释了为什么停药后要观察一两个月才算数: 排空同样有延迟。
性价比分析:
ubiquinone 100 mg × 3 次/天 × 1 年 ≈ ¥600-1200 (按高质量品牌)vs Q-SYMBIO 的临床效益: 极高性价比在心衰患者vs 保健用途: 性价比不高
同一个价签, 在心衰病人身上和在健康人身上的意义天差地别。心衰那一档买的是有硬终点撑着的风险下降; 保健那一档买的是一个还没被验证的可能性。同样的钱、同样的药、完全不同的期望值——这才是决策树真正在分的东西, 而不是药本身好不好。
相关主题:
migraine 故事三剑客之一alpha-lipoic-acid L4 五辅基 (B1/B2/B3/B5 + ALA + Q10 是线粒体系列)niacin-b3/nad + riboflavin-b2/flavins L4 (电子传递链伙伴)cardiovascular/atherosclerosis L4 (心衰背景)statin / 高脂血症患者: 报告规则触发点
Q10 是补剂中少有的有真硬终点 RCT 证据之一, 尤其在心衰适应症。它不是抗衰神药, 而是特定适应症下值得用的辅助治疗。
Quality testing reality
Q10 is one of the most quality-variable supplement categories — independent testing data are striking.ConsumerLab 2022 testing (40 Q10 products):
17 products (42%) had label content ≠ actual content:5 had content < 80% of label7 had content > 120% of label (overage is also a problem)5 contained no or trace Q10 (i.e., counterfeit)Price + brand name ≠ quality: some famous brands tested poorly, some niche brands tested well
Labdoor 2023 evaluation (top 20 Q10):
Gold tier (90+ points): only 5 — partial models from Doctor's Best, Jarrow, Life Extension, Nature Made, Pure EncapsulationsHeavy-metal testing: 1/3 of products slightly exceeded heavy-metal thresholds (still within FDA safety limits)
Third-party certifications (check before purchase):
USP Verified Mark (US Pharmacopoeia): strictest, tests label + purity + heavy metals + microbesNSF International: similar to USP, common for athletesConsumerLab Approved: independent testing + public reportInformed-Choice / Informed-Sport: doping + purity certification (athlete-grade)Labdoor scoring: independent body, public rankings
Risks of "Taobao / JD Q10":
Domestic OTC Q10 rarely carries third-party certificationRecommendation: look for imported brands with USP or NSF marks (Doctor's Best / Jarrow / Now Foods, etc.), purchase the original via JD International / Tmall InternationalAvoid: 100 capsules under ¥100 (actual cost is well below retail → likely counterfeit / inflated labels)
Dose accuracy:
100 mg label = 40-180 mg measured (ConsumerLab data)Even with a good brand, different batches can varyTest annually across batches if feasible (cautious approach)
Form affects cost:
Ubiquinone 100 mg (standard): $0.10-0.30/capsule (USP-certified)Ubiquinol 100 mg: $0.40-0.80/capsule"Nano" / "water-soluble" enhanced bioavailability: $0.60-1.20/capsuleBest value: USP-certified ubiquinone 100 mg, taken with a fatty meal
When to consider stopping:
Continue (Q10 is doing something):
HF: forever (with HF drugs, lifelong)SAMS improvement: continue while on statinMigraine prevention working: re-evaluate after 6-12 months of maintenance
Consider stopping:
3 months without symptom improvement (SAMS / migraine prevention)Side effects (insomnia / GI discomfort / nausea)Financial pressure + first-line interventions (weight loss + training + diet) take prioritySwitching strategies: e.g., switching from statin to non-statin lipid-lowering (PCSK9 inhibitor) for SAMS → no need for Q10
How to stop:
Stop directly: Q10 has no withdrawal effectObserve for 1-2 months: see if symptoms returnIf symptoms return → restart
Atlas practice: do not pay a premium for "anti-ageing" marketing. True indication + third-party-certified brand + with a fatty meal + 3-6 month assessment = informed use.
References · 6
- Mortensen, S. A., Rosenfeldt, F., Kumar, A., Dolliner, P., Filipiak, K. J., Pella, D., et al. (2014). The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO. JACC: Heart Failure, 2(6), 641-649. 10.1016/j.jchf.2014.06.008
- Mortensen, A. L., Rosenfeldt, F., & Filipiak, K. J. (2019). Effect of coenzyme Q10 in Europeans with chronic heart failure: a sub-group analysis of the Q-SYMBIO randomized double-blind trial. Cardiology Journal, 26(2), 147-156. 10.5603/cj.a2019.0022
- Al Saadi, T., Assaf, Y., Farwati, M., Turkmani, K., Al-Mouakeh, A., Shebli, B., et al. (2021). Coenzyme Q10 for heart failure. Cochrane Database of Systematic Reviews, 2021(2). The mortality RR 0.58 (0.35-0.95) rests on ONE study of 420 participants — Q-SYMBIO itself. So this review is not an independent replication of Q-SYMBIO, and it still says there is no convincing evidence either way. 10.1002/14651858.CD008684.pub3
- Bentov, Y., Hannam, T., Jurisicova, A., Esfandiari, N., & Casper, R. F. (2014). Coenzyme Q10 supplementation and oocyte aneuploidy in women undergoing IVF-ICSI treatment. Clinical Medicine Insights: Reproductive Health, 8, 31-36. TERMINATED EARLY over polar-body-biopsy safety concerns; only 24 of a planned 54 completed. Aneuploidy 46.5% vs 62.8%, clinical pregnancy 33% vs 26.7% — NO significant difference, and the authors call it underpowered. It is a negative trial. 10.4137/CMRH.S14681
- Banach, M., Serban, C., Sahebkar, A., et al. (2015). Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clinic Proceedings, 90(1), 24-34. Across 6 RCTs (302 patients), CoQ10 supplementation produced no significant improvement in statin-associated muscle pain or plasma creatine kinase. 10.1016/j.mayocp.2014.08.021
- Taylor, B. A., Lorson, L., White, C. M., & Thompson, P. D. (2015). A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy. Atherosclerosis, 238(2), 329-335. 10.1016/j.atherosclerosis.2014.12.016